Back to Journals » International Journal of Nanomedicine » Volume 10 » Issue 1

Review on lipegfilgrastim

Authors Gasparic M, Leyman S

Received 15 September 2015

Accepted for publication 17 September 2015

Published 3 November 2015 Volume 2015:10(1) Pages 6863—6864

DOI https://doi.org/10.2147/IJN.S96413

Editor who approved publication: Dr Thomas Webster

Download Article [PDF] 

Maja Gasparic, Sophie Leyman

Teva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the Netherlands

Having read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.
The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2
 
 
Read the Corrigendum


Dear editor

Having read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we would therefore like to clarify what lipegfilgrastim actually is.

The description of lipegfilgrastim used in the original article was a “long-acting biosimilar filgrastim”.1 This description was subsequently amended in the corrigendum to “lipegfilgrastim has an active substance that is similar to filgrastim, with similar pharmacokinetics, receptor binding affinity, safety and efficacy as pegfilgrastim”.2

It is true that lipegfilgrastim is not a long-acting biosimilar of filgrastim. It is not approved under the biosimilar classification by the European Medicines Agency, and has its own distinct Anatomical Therapeutic Chemical (ATC) code (ATC code L03AA14, lipegfilgrastim; ATC code L03AA02, filgrastim; ATC code L03AA13, pegfilgrastim).3 Further, we believe lipegfilgrastim would be more accurately described as “glycopegylated, long-acting form of recombinant human filgrastim”.

Furthermore, the original article does not give the correct indications for either filgrastim or lipegfilgrastim (eg, pages 2,648 and 2,649).1 In August 2013, the European Medicines Agency (EMA) approved lipegfilgrastim to be used for reducing the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukemia and myelodysplastic syndromes).4 Lipegfilgrastim is currently marketed throughout Europe with this indication.

Disclosure

Both authors are employees of Teva Pharmaceuticals Europe BV. The authors report no other conflicts of interest in this communication.


References

1.

Hoggatt J, Tate TA, Pelus LM. Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia. Int J Nanomedicine. 2015;10:2647–2652.

2.

Hoggatt J, Tate TA, Pelus LM. Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [corrigendum]. Int J Nanomedicine. 2015;10:5421.

3.

European Commission [webpage on the Internet]. Full human ATC code list. European Commission; 2015. Available from: http://ec.europa.eu/health/documents/community-register/html/atc.htm. Accessed 15 September 2015.

4.

Electronic Medicines Compendium (eMC) [webpage on the Internet]. Lonquex®: summary of product characteristics. Electronic Medicines Compendium (eMC); 2015. Available from: https://www.medicines.org.uk/emc/medicine/28948. Accessed 15 September 2015.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]